Oncogenes and tumor suppressor genes in pituitary tumorigenesis

Frontiers of Hormone Research

Volumn 20, Issue , 1996, Pages 122-136

  Pei, Lin ^a   Melmed, Shlomo ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000691630     PISSN: 03013073     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (116)

1. Knudson AD: All in the (cancer) family. Nat Genet 1993;5:103-106.
2. Herman V, Fagin J, Gonsky R, Kovacs K, Melmed M: Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 1990;71:1427-1433.
3. Alexander JM, Biller BMK, Bikkal H, Zervas NT, Arnold A, Klibanski A: Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest 1990;86:336-340.
4. Steward PM, Carey MP, Graham CT, Wright AD, London DR: Growth hormone secreting pituitary carcinoma: A case report and literature review. Clin Endocrinol 1992;37:189-195.
5. Melmed S: Pituitary neoplasia. Endocrinol Metabol Clin North Am 1994;23:81-92.
6. DeFeo D, Gonda MA, Young H, Chang EH, Lowy DR, et al: Analysis of two divergent rat genomic clones homologous to the transforming gene of Harvey murine sarcoma virus. Proc Natl Acad Sci USA 1981;78:3328-3332.
7. Ellis RW, DeFeo D, Shih TY, Gonda MA, Young HA, et al: The P21 ras genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature 1981;292:506-511.
8. Parada LF, Tabin CJ, Shih C, Weinberg RA: Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 1982;297:474-478.
9. Santos E, Tronick SR, Aaronson SA, Pulciani S, Barbacid M: T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature 1982;298:343-347.
10. Scolnick EM, Papageorge AG, Shih TY: Guanine nucleotide-binding activity as an assay for sre protein of rat-derived murine sarcoma virus. Proc Natl Acad Sci USA 1979;76:5355-5359.
11. Shih TY, Papageorge AG, Stokes PE, Weeks MO, Scolnick EM: Guanine nucleotide-binding and autophosphorylation activities associated with the p21src protein of Harvey murine sarcoma virus. Nature 1980;287:686-691.
12. Tamanoi F, Walsh M, Kataoka T, Wigler M: A product of yeast RAS2 gene is a guanine nucleotide binding protein. Proc Natl Acad Sci USA 1984;81:6924-6928.
13. Temeles GL, Gibbs JB, D'Alonzo JS, Sigal IS, Scolnick EM: Yeast and mammalian Ras proteins have conserved biochemical properties. Nature 1985;313:700-703.
14. Gibbs JB, Sigal IS, Peo M, Scolnick EM: Intrinsic GTPase activity distinguishes normal and oncogenic ras P21 molecules. Proc Natl Acad Sci USA 1984;81:5704-5708.
15. McGrath JP, Capon DJ, Levinson DV: Comparative biochemical properties of normal and activated human ras P21 protein. Nature 1984;310:644-649.
16. Sweet RW, Yokoyama S, Kamata T, Feramisco JR, Rosenberg M, Gross M: The product of ras is a GTPase and T24 oncogenic mutant is deficient in this activity. Nature 1984;311:273-275.
17. Manne V, Bekesi E, Kung HF: Ha-ras proteins exhibit GTPase activity: Point mutations that activate Ha-ras gene products result in decreased GTPase activity. Proc Natl Acad Sci USA 1985;82:376-380.
18. Willumsen BM, Christensen A, Hubbert NL, Papageorge AG, Lowy DR: The P21 ras c-terminus is required for transformation and membrane association. Nature 1984;310:583-586.
19. Fujiyama A, Tamanoi F: Processing abd fatty acid acylation of RAS1 and RAS2 proteins in Saccharmyces cerevisiae. Proc Natl Acad Sci USA 1986;83:1266-1270.
20. Hurley JB, Simon MI, Teplow DB, Robishaw JD, Gilman AG: Homologies between signal transducing G protein and its relationship to ras proteins. Science 1984;226:860-862.
21. Tanabe T, Nukada T, Nishikawa Y, Sugimoto K, Suzuki H, et al: Primary structure of α-subunit of transducin and its relationship to ras proteins. Nature 1985;315:242-245.
22. Lochrie MA, Hurley JB, Simon MI: Sequence of the alpha subunit of photoreceptor G protein: Homologies between transducin, ras, and elongation factors. Science 1985;228:96-99.
23. Itoh H, Kozawa T, Nagata S, Nakamura S, Katada T, et al: Molecular cloning and sequence determination of cDNAs for a subunit of guanine nucleotide-binding proteins Gs, Gi, and Go from rat brain. Proc Natl Acad Sci USA 1986;83:3776-3780.
24. Egan SE, Giddings BW, Brooks MW, Buday L, Sizeland AM, Weinberg RA: Association of Sos ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature 1993;366:41-45.
25. Bollag G, McCormic F: Regulators and effectors of Ras proteins. Annu Rev Cell Biol 1991;7:601-632.
26. Medema RH, Bos JL: The role of P21ras in receptor tyrosine kinase signalling. CRC Crit Rev Oncogene 1993;4:615-661.
27. Bos JL: Ras genes in human cancer: A review. Cancer Res 1989;49:4682-4689.
28. Anderson JA, Irish JC, Ngan BY: Prevalence of ras oncogene mutation in head and neck carcinomas. J Otolaryngol 1992;21:321-326.
29. Karga HJ, Alexander JM, Hedley-Whyte ET, Klibansky A, Jameson JL: Ras mutation in human pituitary tumors. J Clin Endocrinol Metab 1992;72:914-919.
30. Herman V, Drazin NZ, Gonsky R, Melmed M: Molecular screening of pituitary adenomas for gene mutations and rearrangements. J Clin Endocrinol Metab 1993;77:50-55.
31. Boggild MD, Jenkinson S, Pistorello M, Boscaro M, Scanarini M, et al: Molecular genetic studies of sporadic pituitary tumors. J Clin Endocrinol Metab 1994;78:387-392.
32. Pei L, Melmed M, Scheitayer B, Kovacs K, Prager D: H-ras mutations in human pituitary carcinoma metastases. J Clin Endocrinol Metab 1994;78:842-846.
33. Tabin CJ, Bradley SM, Bargmann CI, et al: Mechanism of activation of a human oncogene. Nature 1982;300:199-205.
34. Pai EF, Kasch W, Krengerl V, Homlse KC, Wittinghofer A: Structure of the guanine-nucleotide binding domain of the H-ras oncogene product P21 in the triphosphate conformation. Nature 1989;341:209-214.
35. Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya T: Detection of ras gene mutations in human lung cancers by single-stranded conformation polymorphism analysis of the polymerase chain reaction products. Oncogene 1990;5:1037-1043.
36. Krontiris TG, Devlin B, Kapp DD, Robert NJ, Risch N: An association between the risk of cancer and mutations in HRAS1 minisatellite locus. N Engl J Med 1993;329:517-523.
37. Luscher B, Eisenman RN: New light on myc and myb. Part 1. Myc. Genes Dev 1990;4:2025-2035.
38. Kato GJ, Dang CV: Function of the c-myc oncoprotein. FASEB J 1992;6:3065-3072.
39. Marcu KB, Bossone SA, Petal AJ: Myc function and regulation. Annu Rev Biochem 1992;61:809-860.
40. Evan GI, Littlewood TD: The role of c-myc in cell growth. Curr Opin Genet Dev 1993;3:44-49.
41. Eilers M, Schrim S, Bishop JM: The myc protein activates transcription of the a-prothymosin gene. EMBO J 1991;10:133-141.
42. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, et al: Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992;69:119-128.
43. Wagner AJ, Small MB, Hay N: Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2. Mol Cell Biol 1993;13:2432-2440.
44. Bishop JM: Molecular themes in oncogenesis. Cell 1991;64:235-248.
45. Spencer CA, Groudine M: Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res 1991;56:1-48.
46. Woloschak M, Roberts JL, Post K: C-myc, c-fos, and c-myb gene expression in human pituitary adenomas. J Clin Endocrinol Metab 1994;79:253-257.
47. Daniels M, Harrison D, Raghavan R, et al: C-myc immunoreactivity in human corticotroph adenomas (abstract MP-32). Proc 3rd Int Pituitary Cong 1993.
48. Alitalo K, Winqvist R, Lin CC, De La Chapelle A, Schwab M, Bishop JM: Aberrant expression of an amplified c-myb oncogene in two cell lines from a colon carcinoma. Proc Natl Acad Sci USA 1984;81:4534-5438.
49. Slamon DJ, deKernion JB, Verma IM, Cline MJ: Expression of cellular oncogenes in human malignancies. Science 1984;224:256-262.
50. Introna M, Golay J, Frampton J, Nakano T, Ness SA, Graf T: Mutations in v-myb alter the differentiation of myelomoncytic cell transformed by the oncogene. Cell 1990;63:1287-1297.
51. Rauscher F-J III, Sambucetti LC, Curran T, Distel RJ, Spiegelman BM: Common DNA-binding site for fos protein complexes and transcription factor AP-1. Cell 1988;52:471-480.
52. Muller R, Klempnauer K-H, Moelling K, Vennstromm B, Beug H, Vennstrom B: Cellular oncogenes encoding nuclear proteins: Fos, myb, myc, and erbA; in Klein C (ed): Cellular Oncogene Activation. New York, Dekker, 1988, pp 1-51.
53. UHS, Kelley P, Lee WH: Abnormalities of the human growth hormone gene and protooncogenes in some human pituitary adenomas. Mol Endocrinol 1988;2:85-89.
54. Weinberg RA: Tumor suppressor genes. Science 1991;254:1138-1146.
55. Abramson DH, Ellsworth RM, Kilchin FD, Tung G: Second nonocular tumors in retinoblastoma survivors. Ophthalmology 1984;91:1351-1355.
56. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godboul R, et al: Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 1993;305:779-784.
57. Bookstein R, Lee WH: Molecular genetics of the retinoblastoma suppressor gene. Crit Rev Oncogene 1991;2:211-227.
58. Hamel PA, Phillips RA, Muncaster M, Gallie BL: Speculations on the roles of RB1 in tissue-specific differentiation, tumor initiation and tumor progression. FASEB J 1993;7:846-854.
59. Huang SHJ, Yee JK, Shew J-Y, Chen P-L, Bookstein R, et al: Suppression of the neoplastic phenotype by replacement of the retinoblastoma gene product in human cancer cells. Science 1988;242:1533-1566.
60. Xu H-J, Sumegi J, Hu S-X, Banerjee A, Uzvolgi E, et al: Intraocular tumor formation of RB reconstituted retinoblastoma cells. Cancer Res 1991;51:4481-4485.
61. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 1995;81:323-330.
62. Whyte P, Buchlovich KJ, Horowitz JM, Friend SH, Raybuck M, et al: Association between an oncogene and an anti-oncogene: The adenovirous E1A proteins binds to the retinoblastoma gene product. Nature 1988;334:124-129.
63. Decaprio JA, Ludlow JW, Figge J, Shew J-Y, Huang CM, et al: SV40 large T antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 1988;54:275-283.
64. Rustgi AK, Dyson N, Bernards R: Amino-tcrminal domain of c-myc and N-myc proteins mediate binding to the retinoblastoma gene product. Nature 1991;352:541-544.
65. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR: The E2F transcription factor is a cellular factor for the RB protein. Cell 1991;65:1053-1061.
66. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA: Physical interactions of the retinoblastoma protein with human cyclins. Cell 1993;73:499-511.
67. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J-Y, Livingston DM: Functional interactions of the retinoblastoma protein with mammalian D-type cyclin. Cell 1993;73:487-497.
68. Welch PJ, Wang JYJ: A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-abl tyrosine kinase in cell cycle. Cell 1993;75:779-790.
69. Welch PJ, Wang JYJ: Disruption of retinoblastoma protein function by coexpression of its C procket fragment. Genes Dev 1995;9:31-46.
70. Chen P-L, Scully P, Shew J-Y, Wang JYL, Lee W-H: Phosphorylation of the Rb gene product is modulated during cell cycle and cellular differentiation. Cell 1989;58:1193-1198.
71. Jacks T, Fazelli A, Schmitt E, Bronson RT Goodell M, Weinberg RA: Effects of an Rb mutation in the mouse. Nature 1992;359:295-300.
72. Clark AR, Maadag ER, van Roon M, van der Lugt NMT, van der Valk M, et al: Requirement for a functional Rb-1 gene in murine development. Nature 1992;359:328-330.
73. Lee EY-HP, Chang C-Y, Hu N, Wang Y-CJ, Lai C-C, et al: Mice deficient for Rb are nonviable and show defects in neurogenesis and hematopoiesis. Nature 1992;359:288-294.
74. Lee EY-HP, Hu N, Yuan S-SF, Cox LA, Bradley A, et al: Daul roles of the retinoblastoma protein in cell cycle regulation and neuron differentiation. Genes Dev 1994;8:2008-2021.
75. Δ20/+ mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 1994;9:1021-1027.
76. Cryns VL, Alexander JM, Klibanski A, Arnold A: The retinoblastoma gene in human pituitary tumors. J Clin Endocrinol Metab 1993;77:644-646.
77. Zhu J, Leon SP, Beggs AH, Busque L, Gilliland DG, Black PM: Human pituitary adenomas show no loss of heterozygosity at the retinoblastoma gene locus. J Clin Endocrinol Metab 1994;78:922-927.
78. Woloschak M, Roberts JL, Post KD: Loss of heterozygosity at the retinoblastoma locus in human pituitary tumors. Cancer 1994;74:693-696.
79. Pei L, Melmed M, Scheithauer B, Kovacs K, Benedict WF, Prager D: Frequence loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: Evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res 1995;55:1613-1616.
80. Lane CP, Crawford LV: T-antigen is bound to a host protein in SV40-transformed cells. Nature 1979;278:261-263.
81. Linzer DIH, Levine AJ: Characterization of a 54 k-dalton cellular SV40 tumour antigen present in SV40 transformed cells and uninfected embryonal carcinoma cells. Cell 1979;17:43-52.
82. Fields S, Jang SK: Presence of a potent transcription activating sequence in p53 protein. Science 1990;249:1046-1049.
83. Funk WD, Pak DT, Karas RH, Wright WE, Shay JW: A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 1992;12:2866-2871.
84. Unger T, Nau MM, Segal S, Minna JD: P53: A transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J 1992;11:1383-1390.
85. Miller CW, Chumakov A, Said J, Aslo A, Chen DL, Koeffler HP: Mutant P53 proteins have diverse intracellular abilities to oligomerize and activate transcription. Oncogene 1992;8:1815-1824.
86. Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C: Wild-type p53 activates transcription in vitro. Nature 1992;358:83-86.
87. Kern SE, Pietenpol JA, Thisgalingam S, Seymour A, Kinzler KW, Vogelstein B: Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992;256:1233-1238.
88. Prives C, Manfredi JJ: The p53 tumor suppressor protein: Meeting review. Genes Dev 1993;7:529-534.
89. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM: The E6 oncoprotein encoded by human papillomavirus type 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-1136.
90. Momand J, Zambatti GP, Olson DC, George D, Levine A: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-1245.
91. Harris CC: p53: At the crossroads of molecular carcinogenesis and risk assessment. Science 1993;262:1980.
92. Ei-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B: Definition of a consensus binding site for p53. Nat Genet 1992;1:45-49.
93. Scharer E, Iggo R: Mammalian p53 can function as transcription factor in yeast. Nucleic Acids Res 1992;20:1539-1545.
94. Finlay CA, Hinds PW, Tan T-H, Eliyahu D, Oren M, Levine AJ: Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half live. Mol Cell Biol 1988;8:531-539.
95. Halevy O, Michalovitz D, Oren M: Different tumor-derived p53 mutants exhibit distinct biological activities. Science 1990;250:113-116.
96. Sumi T, Stefancanu L, Kovacs K, Asa SL, Rindin G: Immunohistochemistry study of p53 protein in human and animal pituitary tumors. Endocr Pathol Update 1993;4:95-99.
97. Harvey M, Vogel H, Lee EY-HP, Bradley A, Donehower L-A: Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Res 1995;55:1146-1151.
98. Larsson C, Skogseid B, Ober K, et al: Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988;332:85-87.
99. Fujimori M, Wells SA, Nakamura Y: Fine mapping of the gene responsible for multiple endocrine neoplasia type 1 (MEN1). Am J Hum Genet 1992;55:399-403.
100. Iwasaki H, Steward PW, Dilley WG, et al: A minisatellite and microsatellite polymorphism within 1.5 kb at the human muscle glycogen phosphorylase (PYGM) locus can be amplified by PCR and have combined informativeness of PIC 0.95. Genomics 1992;13:7-15.
101. Larsson C, Weber G, Kvanta E, et al: Isolation and mapping of polymorphic cosmid clones used for sublocalization of the multiple endocrine neoplasia type 1 (MEN1) locus. Hum Genet 1992;89:187-183.
102. Friedman E, Sakaguchi K, Bale AE, et al: Clonality of parathyroid tumors in familial multiple endocrine neoplasia type 1. N Engl J Med 1989;321:213-217.
103. Thakker R, Bouloux P, Wooding C, et al: Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N Engl J Med 1989;321:218-224.
104. Bystrom C, Larsson C, Blomberg C, et al: Localization of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors. Proc Natl Acad Sci USA 1990;87:1968-1972.
105. Bale AE, Norton JA, Wong EL, et al: Allelic loss on chromosome 11 in hereditary and sporadic tumors related to familial multiple endocrine neoplasia type 1. Cancer Res 1991;51:1154-1157.
106. Thakker RV, Pook MA, Wooding C, et al: Association of somatotrophinomas with loss of alleles on chromosome 11 and with gsp mutations. J Clin Invest 1993;91:2815-2821.
107. Ballester R, Marchuk D, Bohuski M, Saulino A, Letcher R, Wigler M, Collins F: The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 1990;63:851-859.
108. Martin GA, Viskochil D, Bollag G, et al: The GAP-relatcd domain of the neurofibromatosis type 1 gene product interact with ras p21. Cell 1990;63:843-849.
109. Xu G, Lin B, Tanaka K, et al: The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 1990;63:835-841.
110. Xu G, O'Connell P, Viskochil D, et al: The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990;62:599-608.
111. Li Y, Bollag G, Clark R, et al: Somatic mutations in the neurofibromatosis 1 gene in human tumors. Cell 1992;69:275-281.
112. Pei L, Melmed M: The neurofibromatosis gene in human pituitary adenomas. Endocr Pathol Update 1994;5:220-232.
113. Gale NW, Kaplan S, Lowenstein EJ, Schlessinger J, Bar-Sagi D: Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras. Nature 1993;363:88-92.
114. Li N, Batzer A, Daly R, et al: Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and link receptor tyrosine kinase to Ras signaling. Nature 1993;363:85-88.
115. Rozakis-Adcock M, Fernley R, Wade J, Pawson T, Bowtell D: The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature 1993;363:83-85.
116. 21ras activation and binds to sevenless and Sos protein in vitro. Cell 1993;73:169-177.